Diabetes & Endocrinology – Page 4

Diabetes & Endocrinology news Public Health

Disentangling Clinical and Preclinical Obesity: Their Distinct Impacts on All-Cause Mortality Risk in the UK Biobank Study

By MedXY 10/29/2025

New evidence from the UK Biobank reveals that clinical obesity, defined by obesity-related dysfunctions, significantly elevates all-cause mortality risk. Early detection and intervention are key to reducing mortality associated with both preclinical and clinical obesity.

Diabetes & Endocrinology news Public Health

Sustained Impact of Lifestyle and Metformin Interventions on Type 2 Diabetes Prevention: Insights from 21 Years of the US DPP Trial

By MedXY 10/29/2025

Over 21 years, intensive lifestyle changes and metformin significantly reduced type 2 diabetes incidence in at-risk adults, with variable effects based on individual baseline risk factors, highlighting opportunities for precision prevention.

AI Clinical Updates Diabetes & Endocrinology news

Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program

By MedXY 10/29/2025

This review examines the first phase 3 randomized trial demonstrating that an AI-powered Diabetes Prevention Program lifestyle intervention is noninferior to human coaching in improving weight loss, HbA1c, and physical activity among adults with prediabetes and overweight or obesity.

Diabetes & Endocrinology Gastroenterology news

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

By MedXY 10/28/2025

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver health, glycemic control, and lipid profiles, underscoring potential dietary strategies for MASLD management.

Diabetes & Endocrinology Gastroenterology news

Time-Restricted Eating as a Promising Approach for Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence from a Randomized Controlled Trial

By MedXY 10/28/2025

A 16-week RCT demonstrates that time-restricted eating significantly reduces hepatic steatosis in MASLD, offering comparable metabolic benefits to calorie restriction without adverse events.

Diabetes & Endocrinology General Surgery news

Bariatric Surgery Significantly Reduces Risk of Developing Major Obesity-Related Comorbidities: Insights from a Large Veterans Cohort

By MedXY 10/27/2025

A large retrospective cohort study reveals bariatric surgery markedly lowers the incidence of key metabolic comorbidities compared to weight management alone in obese veterans, supporting its role in durable obesity-related risk reduction.

Diabetes & Endocrinology news Pediatrics

Automated Insulin Delivery Systems: Transforming Glucose Management in Youth with Type 1 Diabetes

By MedXY 10/27/2025

Automated insulin delivery (AID) systems significantly improve glucose control and reduce hypoglycemia and hyperglycemia in children and adolescents with type 1 diabetes, without increasing adverse events.

Diabetes & Endocrinology news Ophthalmology

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

By MedXY 10/26/2025

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudative AMD.

Diabetes & Endocrinology Oncology

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

By MedXY 10/25/2025

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.

Diabetes & Endocrinology news Ophthalmology

Impact of Multifactorial Interventions on Retinopathy in Type 2 Diabetes: Insights from the J-DOIT3 Trial

By MedXY 10/24/2025

This analysis highlights how intensive multifactorial management and glycemic control influence diabetic retinopathy onset, emphasizing the risks associated with hypoglycemia despite good glycemic control.

Diabetes & Endocrinology OB/GYN & Women's Health

Closed-Loop Insulin Delivery in Type 1 Diabetes During Pregnancy: Insights from the CIRCUIT Randomized Clinical Trial and Contemporary Evidence

By MedXY 10/24/2025

The CIRCUIT trial demonstrates that closed-loop insulin delivery significantly improves glycemic control during pregnancy in type 1 diabetes, increasing time in pregnancy-specific glucose range and reducing hypoglycemia risks relative to standard care.

Diabetes & Endocrinology OB/GYN & Women's Health Specialties

Navigating the Frontiers of Premature Ovarian Insufficiency Research: Insights from the Top 100 Influential Articles

By MedXY 10/22/2025

A comprehensive bibliometric analysis of the 100 most-cited articles in premature ovarian insufficiency reveals key research trends, leading contributors, and emerging scientific directions in genetics, cardiovascular disease, and immunology.

Diabetes & Endocrinology HIV/AIDS Internal Medicine Specialties

Nucleoside Reverse Transcriptase Inhibitors: A Novel Therapeutic Avenue Against Inflammaging and Age-Related Diseases

By MedXY 10/22/2025

NRTIs, traditionally used in HIV and HBV treatment, demonstrate promising anti-inflammatory effects that may reduce the incidence of age-related diseases by inhibiting inflammaging processes associated with endogenous retroelements.

Diabetes & Endocrinology Psychiatry Specialties

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

By MedXY 10/22/2025

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychiatric symptoms.

Diabetes & Endocrinology news Public Health

Leveraging the Planetary Health Diet to Reduce Type 2 Diabetes Risk and Environmental Impact: Insights from the EPIC-Norfolk Study

By MedXY 10/20/2025

Higher adherence to the planetary health diet is linked with a 32% reduced risk of type 2 diabetes and significantly lower greenhouse gas emissions, supporting its role in preventing diabetes and promoting sustainability.

Diabetes & Endocrinology Family Medicine & Nutrition Public Health Specialties

Planetary Health and Plant-Based Diets: Reducing Type 2 Diabetes Risk in UK Adults

By MedXY 10/20/2025

Higher adherence to the Planetary Health Diet Index, reflecting environmentally sustainable plant-based eating patterns, is strongly associated with reduced type 2 diabetes risk in UK Biobank participants, comparable or superior to other established plant-based diet scores.

Cardiology Diabetes & Endocrinology news

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

By MedXY 10/19/2025

This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes status.

Cardiology Diabetes & Endocrinology Specialties

Triglyceride Glucose-Waist Height Ratio Index as a Predictor of Cardiometabolic Multimorbidity in Chinese Middle-Aged and Older Adults: Insights from a National Prospective Cohort Study

By MedXY 10/19/2025

This study demonstrates that the triglyceride glucose-waist height ratio (TyG-WHtR) index independently predicts cardiometabolic multimorbidity risk in Chinese adults aged ≥45, showing a linear dose-response relationship and improved predictive performance over traditional metrics.

Cardiology Diabetes & Endocrinology news

Joint Impact of TyG-Related Indices and eGDR on Cardiometabolic Multimorbidity Risk in Chinese Adults: Insights from a Nationwide Cohort

By MedXY 10/19/2025

This study elucidates that high triglyceride glucose (TyG) related indices combined with low estimated glucose disposal rate (eGDR) synergistically elevate cardiometabolic multimorbidity (CMM) risk in middle-aged and older Chinese adults, enhancing early risk stratification and prevention strategies.

Cardiology Diabetes & Endocrinology Nephrology news

Insulin Resistance Indices as Predictors of Cardio-Renal-Metabolic Multimorbidity: Insights from the UK Biobank

By MedXY 10/19/2025

This study demonstrates that insulin resistance indices, particularly TyG-WC, TyG-WHtR, and METS-IR, robustly predict the risk and progression of cardio-renal-metabolic multimorbidity, with inflammation and kidney function mediating these associations.